NEUROBiOGEN

Privately held: no public share price · South Korea

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
MAO-BSmall molecule
ObesityAlzheimer's Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
January 2027 (1)
TisolagilinePhase 2Overweight, Obesity, Obese Patients
Est. primary completion 2027-01-31 · NCT07009171 · CT.gov ↗
What to watch
June 2027 (1)
TisolagilinePhase 2Mild Cognitive Impairment (MCI), Mild Dementia, Alzheimer's Disease
Est. primary completion 2027-06-30 · NCT07027072 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.